No, Medicare does not currently cover a plasma pTau217 test for routine Alzheimer's evaluation. A pTau217 test measures phosphorylated tau 217 in blood, a marker linked to amyloid plaques in the brain, and beneficiaries should expect to pay out of pocket. The test is meant to help evaluate memory or thinking symptoms, not to screen healthy people. That distinction drives both medical guidance and payment decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Register through CMS’s official page — Use this page to review requirements and register directly.
Table of Contents
- What does this blood test measure?
- Who should get tested?
- Why won't Medicare pay for routine use?
- What will it cost and what should you do next?
What does this blood test measure?
The U.S. Food and Drug Administration cleared Fujirebio's Lumipulse G pTau217/beta-Amyloid 1-42 plasma ratio on May 16, 2025, for detection of amyloid plaques in adults age 55 and older with signs and symptoms of Alzheimer's disease, according to the FDA clearance announcement.
The result is a ratio between two blood proteins, not a simple positive or negative reading. The FDA states the test only aids diagnosis, is not cleared for screening or as a stand-alone diagnosis, and must be interpreted with other clinical evaluations. A doctor still needs history, cognitive testing, and often brain imaging or follow-up.
Who should get tested?
The Alzheimer's Association guideline released July 29, 2025, limits blood-biomarker testing to patients with objective cognitive impairment seen in specialized care, not routine primary-care screening, according to the Association guideline release. Objective impairment means measurable problems on exam or testing, not self-reported forgetfulness alone.
In practice, that points to a memory clinic, neurology, or geriatrics visit after initial screening. A person with progressive word-finding trouble, getting lost in familiar places, or declining work performance fits the intended group better than someone seeking reassurance without symptoms.
Why won't Medicare pay for routine use?
Medicare does not currently cover Alzheimer's blood-biomarker tests for routine use, and particularly does not cover pre-symptom screening, according to the Being Patient coverage guide. FDA clearance alone does not create Medicare coverage. Reviewers also found no national coverage determination for the newer pTau217 tests as of August 2026.
Medicare has taken a narrower path for related Alzheimer's care. The Centers for Medicare and Medicaid Services covers amyloid-targeting drugs only for enrolled beneficiaries with mild cognitive impairment or mild dementia whose physicians participate in a registry collecting real-world evidence. Blood tests ordered outside that kind of covered pathway remain patient-paid.
What will it cost and what should you do next?
A Medicare beneficiary seeking a pTau217 evaluation should expect out-of-pocket payment, reported around $277 for Labcorp's single p-tau217 test and from $399 for Quest tests, with broader panels higher, according to the Being Patient pricing review. Hospital fees, interpretation, and follow-up visits can add to that amount. Use these steps before you order the test: Bring your medication list, symptom timeline, and a family member who has seen the changes to that visit.
- Document symptoms, onset dates, medications, and family history.
- Ask your doctor for referral to specialized cognitive care for objective testing.
- Ask the lab for the exact test name, price in writing, and whether a panel costs more.
- Ask how the result will change care, including eligibility for treatment or trials.
